Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb-Infected Adults

Autor: F Perrin, H Bettinson, M Riste, Daniel B. Wright, Stephanie A. Harris, Catherine Cosgrove, Alison M. Lawrie, Samantha Vermaak, Paul Moss, Marc Lipman, Fergus V. Gleeson, Christopher P. Conlon, Helen McShane, Jennifer L. Marshall, R Powell Doherty, Iman Satti, Rachel Wittenberg, Martin Dedicoat, Morven Wilkie, R Lopez Ramon

Publikováno v: Vaccines
Volume 9
Issue 4
Vaccines, Vol 9, Iss 396, p 396 (2021)

The immunogenicity of the candidate tuberculosis (TB) vaccine MVA85A may be enhanced by aerosol delivery. Intradermal administration was shown to be safe in adults with latent TB infection (LTBI), but data are lacking for aerosol-delivered candidate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8572cfa07e14d4e5e36473d0dd38436
http://europepmc.org/articles/PMC8073411

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb -Infected Adults.

Autor: Riste M; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.; Department of Infection and Tropical Medicine, Heartlands Hospital, Birmingham B9 5SS, UK., Marshall JL; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Satti I; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Harris SA; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Wilkie M; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Lopez Ramon R; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Wright D; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Wittenberg RE; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Vermaak S; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Powell Doherty R; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Lawrie A; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK., Conlon CP; Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, UK., Cosgrove C; TB Chest Clinic, St George's University Hospitals NHS Foundation Trust, London SW15 5PN, UK., Gleeson F; Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK., Lipman M; Royal Free London NHS Foundation Trust, London NW3 2QG, UK.; UCL Respiratory, University College London, London NW3 2PF, UK., Moss P; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK., Perrin F; Respiratory Medicine, King's College Hospital NHS Foundation Trust, London SE5 9PJ, UK., Dedicoat M; Department of Infection and Tropical Medicine, Heartlands Hospital, Birmingham B9 5SS, UK., Bettinson H; Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Trust, Oxford OX3 7LE, UK., McShane H; The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.

Publikováno v: Vaccines [Vaccines (Basel)] 2021 Apr 16; Vol. 9 (4). Date of Electronic Publication: 2021 Apr 16.